Codagenix Inc
CAGE Code: 5D8K5
NCAGE Code: 5D8K5
Status: Active
Type: Commercial Supplier
Dun & Bradstreet (DUNS): 829942437
Summary
Codagenix Inc is an Active Commercial Supplier with the Cage Code 5D8K5 and is tracked by Dun & Bradstreet under DUNS Number 829942437..
Address
3 Bioscience Park Dr Bldg Ii Ste 501
Farmingdale NY 11735
United States
Points of Contact
No Points of Contact...
Related Information
People who viewed this 'CAGE Code' also viewed...
Snack Time Services Inc Long Island Forum For Technology Champion Aircraft Supply Corp American Playtime Systems Inc Davidson Aluminum And Metals Corp Uniwave Inc Aircraft Tool Co Bay Fireworks Inc A P C Components Inc. Advent Machine Tool Inc St James Gourmet Inc S And W Framing Supplies Inc Graphic Impressions Proline Filter Systems Inc Marine Manifold Corp Miles Petroleum Co. Inc. Seely Equipment & Supply Co Inc Superweld Co Inc Neb Business Systems Inc Fox Equipment Co
Frequently Asked Questions (FAQ) for CAGE 5D8K5
- What is CAGE Code 5D8K5?
- 5D8K5 is the unique identifier used by NATO Organizations to reference the physical entity known as Codagenix Inc located at 3 Bioscience Park Dr Bldg Ii Ste 501, Farmingdale NY 11735, United States.
- Who is CAGE Code 5D8K5?
- 5D8K5 refers to Codagenix Inc located at 3 Bioscience Park Dr Bldg Ii Ste 501, Farmingdale NY 11735, United States.
- Where is CAGE Code 5D8K5 Located?
- CAGE Code 5D8K5 is located in Farmingdale, NY, USA.
Contracting History for CAGE 5D8K5 Most Recent 25 Records
- 75A50123C00048
- Conduct A Phase 2B Efficacy Study As Prescribed In Aoi15 With Coviliv A Proprietary Live Attenuated Virus Covid-19 Vaccine.
- 30 Oct 2023
- Conduct A Phase 2B Efficacy Study As Prescribed In Aoi15 With Coviliv A Proprietary Live Attenuated Virus Covid-19 Vaccine.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $10,000,000.00
- Department Of Health And Human Services (Hhs)
- 75A50123C00048
- Conduct A Phase 2B Efficacy Study As Prescribed In Aoi15 With Coviliv A Proprietary Live Attenuated Virus Covid-19 Vaccine.
- 27 Sep 2023
- Conduct A Phase 2B Efficacy Study As Prescribed In Aoi15 With Coviliv A Proprietary Live Attenuated Virus Covid-19 Vaccine.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $10,000,000.00
- Department Of Health And Human Services (Hhs)
- 75A50123C00048
- Conduct A Phase 2B Efficacy Study As Prescribed In Aoi15 With Coviliv A Proprietary Live Attenuated Virus Covid-19 Vaccine.
- 14 Nov 2023
- Conduct A Phase 2B Efficacy Study As Prescribed In Aoi15 With Coviliv A Proprietary Live Attenuated Virus Covid-19 Vaccine.
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $10,000,000.00
- Department Of Health And Human Services (Hhs)
- W81XWH19C0051
- Army 2017.1 Sbir Phase Ii Medical R&D Contract For Proposal #A2-7469, Titled: "Development Of A Flexible, Live Tetravalent Dengue Vaccine" Log 18263006 - Change In Subcontractor
- 14 Jun 2021
- Army 2017.1 Sbir Phase Ii Medical R&D Contract For Proposal #A2-7469, Titled: "Development Of A Flexible, Live Tetravalent Dengue Vaccine" Log 18263006 - Change In Subcontractor
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $947,584.12
- Department Of Defense (Dod)
- W81XWH19C0051
- Army 2017.1 Sbir Phase Ii Medical R&D Contract For Proposal #A2-7469, Titled: "Development Of A Flexible, Live Tetravalent Dengue Vaccine" Log 18263006 - 889 Compliance And Administrative Changes
- 13 Nov 2020
- Army 2017.1 Sbir Phase Ii Medical R&D Contract For Proposal #A2-7469, Titled: "Development Of A Flexible, Live Tetravalent Dengue Vaccine" Log 18263006 - 889 Compliance And Administrative Changes
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $947,584.12
- Department Of Defense (Dod)
- W81XWH19C0051
- Army 17.1 Sbir Phase Ii Medical R&D Contract For Proposal #A2-7469, Titled "Development Of A Flexible, Live Tetravalent Dengue Vaccine" Erms18263006
- 4 Apr 2019
- Army 17.1 Sbir Phase Ii Medical R&D Contract For Proposal #A2-7469, Titled "Development Of A Flexible, Live Tetravalent Dengue Vaccine" Erms18263006
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $947,584.12
- Department Of Defense (Dod)
- W81XWH19C0051
- Army 2017.1 Sbir Phase Ii Medical R&D Contract For Proposal #A2-7469, Titled: "Development Of A Flexible, Live Tetravalent Dengue Vaccine" Log 18263006 - 12 Month No Cost Extension
- 15 Sep 2021
- Army 2017.1 Sbir Phase Ii Medical R&D Contract For Proposal #A2-7469, Titled: "Development Of A Flexible, Live Tetravalent Dengue Vaccine" Log 18263006 - 12 Month No Cost Extension
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $947,584.12
- Department Of Defense (Dod)
- W81XWH19C0051
- Army 2017.1 Sbir Phase Ii Medical R&D Contract For Proposal #A2-7469, Titled: "Development Of A Flexible, Live Tetravalent Dengue Vaccine" - Log #18263006 - Year 2 Incremental Funding
- 30 Mar 2020
- Army 2017.1 Sbir Phase Ii Medical R&D Contract For Proposal #A2-7469, Titled: "Development Of A Flexible, Live Tetravalent Dengue Vaccine" - Log #18263006 - Year 2 Incremental Funding
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $947,584.12
- Department Of Defense (Dod)
- W81XWH19C0051
- Army 17.1 Sbir Phase Ii Medical R&D Contract For Proposal #A2-7469, Titled: "Development Of A Flexible, Live Tetravalent Dengue Vaccine" Log 18263006 - Change Contracting Officer's Representative And 9-Month No Cost Extension
- 21 Jul 2020
- Army 17.1 Sbir Phase Ii Medical R&D Contract For Proposal #A2-7469, Titled: "Development Of A Flexible, Live Tetravalent Dengue Vaccine" Log 18263006 - Change Contracting Officer's Representative And 9-Month No Cost Extension
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $947,584.12
- Department Of Defense (Dod)
- N3239817P0332
- Igf::Ot::Igf Research Scientist Mfr Dengue Vaccine.
- 11 Apr 2017
- Igf::Ot::Igf Research Scientist Mfr Dengue Vaccine.
- Naval Medical Research Center
- Department Of Defense (Dod)
- $63,991.00
- Department Of Defense (Dod)
- W81XWH18C0046
- Army 17.1 Sbir Phase I Medical R&D Contract For Proposal #A171-067-0379, Titled: "Development Of A Balanced And Efficacious Live-Attenuated Tetravalent Dengue Vaccine" Erms 17152008 - Exercise 4-Month Option Period
- 28 Nov 2018
- Army 17.1 Sbir Phase I Medical R&D Contract For Proposal #A171-067-0379, Titled: "Development Of A Balanced And Efficacious Live-Attenuated Tetravalent Dengue Vaccine" Erms 17152008 - Exercise 4-Month Option Period
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $148,851.02
- Department Of Defense (Dod)
- W81XWH18C0046
- Igf::Ot::Igf Army Sbir Ph I Proposal A171-067-0379 Development Of A Balanced And Efficacious Live-Attenuated Tetravalent Dengue Vaccine Erms17152008
- 9 Nov 2017
- Igf::Ot::Igf Army Sbir Ph I Proposal A171-067-0379 Development Of A Balanced And Efficacious Live-Attenuated Tetravalent Dengue Vaccine Erms17152008
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $99,991.59
- Department Of Defense (Dod)